(532b) Manufacturing and Design of a COVID-19 Vaccine Antigen for Global Access
AIChE Annual Meeting
Wednesday, November 10, 2021 - 3:30pm to 3:54pm
Here, we present a two-pronged approach of host-cell and protein engineering to improve global access to RBD-based vaccines. We genetically engineered K. phaffii to secrete the RBD without typical methanol-induction, which improved upstream titers ~5x and enabled longer production campaigns. We also rationally engineered an RBD protein with improved manufacturing titers and enhanced immunogenicity and antigenicity, enabling smaller dose sizes for wider vaccine distribution. The platform for RBD manufacturing presented here has been transferred to a GMP facility for manufacturing and clinical trials of engineering RBD antigens. This translational success suggests that the strain and protein engineering techniques presented here will be applicable to a wide range of protein therapeutics.